Vivo Panda Fund discloses 3.8% Bolt Biotherapeutics (BOLT) ownership in 13G/A

Rhea-AI Filing Summary

Vivo Panda Fund, L.P., an investor in Bolt Biotherapeutics, Inc., reports beneficial ownership of 72,414 shares of Bolt common stock, representing 3.8% of the class, in this amended Schedule 13G. The percentage is based on 1,919,441 shares outstanding as of November 5, 2025, as disclosed in Bolt’s Form 10-Q. Other affiliated Vivo Capital funds now report 0 shares and 0% ownership. The filers certify the shares are not held to change or influence control of Bolt.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Bolt Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

097702203

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 097702203

1

Names of Reporting Persons

Vivo Capital Fund VIII, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 097702203

1

Names of Reporting Persons

Vivo Capital Surplus Fund VIII, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 097702203

1

Names of Reporting Persons

Vivo Capital VIII, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 097702203

1

Names of Reporting Persons

Vivo Panda Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 72,414.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 72,414.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

72,414.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.8 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The number represents shares of common stock, par value 0.00001 (the "Common Stock") of Bolt Biotherapeutics, Inc. (the "Issuer"), which are held of record by Vivo Panda Fund, L.P. Vivo Panda, LLC is the general partner of Vivo Panda Fund, L.P. The percentage is based on 1,919,441 shares of Common Stock of the Issuer outstanding as of November 5, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission ("the "SEC") on November 12, 2025.

SCHEDULE 13G

CUSIP No. 097702203

1

Names of Reporting Persons

Vivo Panda, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 72,414.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 72,414.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

72,414.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Panda Fund, L.P. Vivo Panda, LLC is the general partner of Vivo Panda Fund, L.P. The percentage is based on 1,919,441 shares of Common Stock of the Issuer outstanding as of November 5, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bolt Biotherapeutics, Inc.
(b)	Address of issuer's principal executive offices: 900 Chesapeake Drive Redwood City, California 94063
Item 2.
(a)	Name of person filing: This Amendment No. 2 to Schedule 13G is filed jointly by Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P., Vivo Capital VIII, LLC, Vivo Panda Fund, L.P. and Vivo Panda, LLC.
(b)	Address or principal business office or, if none, residence: 192 Lytton Avenue, Palo Alto, CA 94301
(c)	Citizenship: Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Panda Fund, L.P. are Delaware limited partnerships. Vivo Capital VIII, LLC and Vivo Panda, LLC are Delaware limited liability companys.
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 097702203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (1) Vivo Capital VIII, LLC Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. are the record holders of 0 shares of the Issuer's shares of Common Stock. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. (2) Vivo Panda, LLC The 72,414 shares of Common Stock are held of record by Vivo Panda Fund, L.P. Vivo Panda, LLC is the general partner of Vivo Panda Fund, L.P.
(b)	Percent of class: Vivo Capital Fund VIII, L.P. 0% Vivo Capital Surplus Fund VIII, L.P. 0% Vivo Capital VIII, LLC: 0% Vivo Panda Fund, L.P.: 3.8% Vivo Panda, LLC: 3.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Vivo Capital Fund VIII, L.P.: 0 shares Vivo Capital Surplus Fund VIII, L.P.: 0 shares Vivo Capital VIII, LLC: 0 shares Vivo Panda Fund, L.P.: 72,414 shares Vivo Panda, LLC: 72,414 shares
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: Vivo Capital Fund VIII, L.P.: 0 shares Vivo Capital Surplus Fund VIII, L.P.: 0 shares Vivo Capital VIII, LLC: 0 shares Vivo Panda Fund, L.P.: 72,414 shares Vivo Panda, LLC: 72,414 shares
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Capital Fund VIII, L.P.

Signature:	/s/ Frank Kung
Name/Title:	Frank Kung/Managing Member of Vivo Capital VIII, LLC, General Partner
Date:	02/13/2026

Vivo Capital Surplus Fund VIII, L.P.

Signature:	/s/ Frank Kung
Name/Title:	Frank Kung/Managing Member of Vivo Capital VIII, LLC, General Partner
Date:	02/13/2026

Vivo Capital VIII, LLC

Signature:	/s/ Frank Kung
Name/Title:	Frank Kung/Managing Member
Date:	02/13/2026

Vivo Panda Fund, L.P.

Signature:	/s/ Frank Kung
Name/Title:	Frank Kung/Managing Member of Vivo Panda, LLC, General Partner
Date:	02/13/2026

Vivo Panda, LLC

Signature:	/s/ Frank Kung
Name/Title:	Frank Kung/Managing Member
Date:	02/13/2026

FAQ

What ownership in Bolt Biotherapeutics (BOLT) does Vivo Panda Fund report?

Vivo Panda Fund, L.P. reports beneficial ownership of 72,414 shares of Bolt Biotherapeutics common stock. This stake represents 3.8% of the company’s outstanding common shares, based on 1,919,441 shares outstanding as of November 5, 2025 disclosed in Bolt’s Form 10-Q.

Which Vivo Capital entities report zero ownership in Bolt Biotherapeutics (BOLT)?

Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital VIII, LLC each report beneficial ownership of 0 shares of Bolt Biotherapeutics common stock. For each of these entities, the filing shows 0% of the outstanding class and no voting or dispositive power.

How is the 3.8% Bolt Biotherapeutics (BOLT) ownership percentage calculated?

The reported 3.8% ownership for Vivo Panda Fund, L.P. and Vivo Panda, LLC is based on 1,919,441 shares of Bolt Biotherapeutics common stock outstanding as of November 5, 2025. This outstanding share figure comes from Bolt’s Quarterly Report on Form 10-Q filed on November 12, 2025.

Who is the general partner of Vivo Panda Fund in the Bolt Biotherapeutics (BOLT) filing?

The filing states that Vivo Panda, LLC is the general partner of Vivo Panda Fund, L.P.. Both entities report beneficial ownership of the same 72,414 Bolt Biotherapeutics common shares, corresponding to 3.8% of the outstanding class as of November 5, 2025.

Does the Vivo Panda stake in Bolt Biotherapeutics (BOLT) aim to influence control?

The signatory certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Bolt Biotherapeutics. The filing also states they are not held in connection with any transaction having that purpose, except activities related to a nomination under Rule 14a-11.

What is the event date for this amended Bolt Biotherapeutics (BOLT) Schedule 13G?

The event that triggered this amended Schedule 13G is dated December 31, 2025. This date marks the point at which the reporting information, including the 3.8% ownership by Vivo Panda Fund, L.P., became relevant for disclosure under the beneficial ownership reporting rules.